Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this ...

All on news it just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which included $375 million in cash payments and $225 million in shares. Plus, Nancy Pelosi ...

Adjusted EBITDA for 2025: Expected to be approximately $5 million. Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years.

Tempus announced its acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing in November and the deal closed earlier this month. Ambry will continue to operate ...

The Bureau of Labor Statistics reported Wednesday that February prices for food and services haven’t gone up as much as many ...

Linh H. Le is an accomplished finance and accounting executive with extensive knowledge and expertise that he has implemented ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other AI stocks in ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

This growth was supported by strategic initiatives such as the acquisition of Ambry Genetics and the launch of new products. The company is positioning itself as a leader in genomic profiling and ...